AIM
NBRV

Acrospire Investment Management’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Acrospire Investment Management’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-2
Closed -$3K – 2256
2016
Q2 		$3K Buy
+2
New +$4.03K ﹤0.01% 1928

Other funds holding NBRV

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Acrospire Investment Management's NBRV Position: Q3 2016 in Review

Acrospire Investment Management sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q3 2016, closing a stake of 2 shares — an estimated $3K sold.

Acrospire Investment Management first reported a position in NBRV in Q2 2016 and held it in 1 quarter. The position peaked at $3K in Q2 2016. 19 funds tracked by Wall St. Rank hold NBRV as of Q3 2016.

  • Acrospire Investment Management reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q3 2016 after selling out during the quarter.
  • Acrospire Investment Management sold 2 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q3 2016, an estimated $3K.
  • Acrospire Investment Management first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q2 2016 and held it in 1 quarter.
  • Acrospire Investment Management's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $3K in Q2 2016.
  • 19 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q3 2016.

Based on Acrospire Investment Management's 13F filing for Q3 2016, filed 10 Nov 2016.